Abstract

Despite significant advancements in therapeutic approaches to triple-negative breast cancer, treatments remain relatively ineffective once metastasis occurs. The introduction of immunotherapy has revolutionized oncological therapies, yet significant hurdles remain before its full potential can be realized. In this review, we examine immune escape mechanisms shared between pregnancy (the ‘fetal allograft’) and cancer. We discuss the use of abortion-inducing agents in the context of cancer immunotherapy, and we also provide rationale and preliminary data on FloraStilbene™, a combination of the polyphenol antioxidant pterostilbene and the glucocorticoid receptor antagonist mifepristone, for the stimulation of anticancer immunity.

Keywords

triple-negative breast cancer, metastasis, cancer immunotherapy, immune escape mechanisms, fetal allograft, pregnancy and cancer parallels, abortion-inducing agents, florastilbene™, immune modulation.